Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting
May 12, 2020

The ODM DUR Board meeting was called to order at 12:00 PM EST via GoToMeeting
https://attendee.gotowebinar.com/register/2953326021978141965
Michael Dietz, D.O. presided

The following Board members were present:
Scott Baran, R.Ph.
David Brookover, R.Ph.
Michael Dietz, D.O., Chair
Michael Farrell, M.D.
Robert Kubasak, R.Ph.
A. Mehran Mostafavifar, M.D.
Lenard G. Presutti, D.O.
Stacey Rexrode-Brewer Pharm.D., Co-Chair
Donald Sullivan Ph.D., R.Ph.

Also present from ODM were Tracey Archibald, Pharm.D., Michelle Barger, Pharm.D., Sean Eckard, B.S. Pharm. D. Change Healthcare attendees included Jill R.K. Griffith B.S. Pharm. D., Gail Master, R.Ph., and Philip Verret, Pharm.D. Approximately 35 observers were present.

The Conflict of Interest Statement

The Conflict of Interest Statement was reviewed with the Board.

Roll Call and Review of Previous Minutes

The February 11, 2020 DUR Board Meeting Minutes were approved.

DUR Committee Report

G. Master presented the re-review results from the intervention directed at members who received a prescription for Tamiflu but did not receive a flu shot during the previous flu season. A discussion ensued about alternative communication methods aimed at improving outcomes if this intervention were to be conducted again.

Next, G. Master presented the intervention directed at prescribers whose patients are taking opioids together with greater than 2,400mg/day of gabapentin. She explained that this intervention has not been mailed out yet. The Board reviewed the letter.

Lastly, G. Master provided an update to the Board on the Coordinated Services Program (CSP) membership. There are currently 215 Fee-for-Service members enrolled in the program.
Health Plan Policy Update

S. Baran presented the Health Plan Policy update. He announced that ODM has implemented emergency changes due to the COVID-19 pandemic.

Next, he announced CMS has issued the FFY 2019 Annual DUR Report template to the States. Like last year’s survey, it will include information on both Fee-For-Service and Managed Care Plan DUR programs. Also, he stated ODM submitted and received CMS approval on the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act State Plan Amendment, also referred to as the SUPPORT Act SPA.

Lastly, he announced that every two years, ODM conducts a Cost of Dispensing Survey. This survey is administered to ODM enrolled pharmacies and a final report is generated and posted on the Medicaid Pharmacy website. This survey is slated to occur later this year.

Unfinished Business

G. Master informed the Board that the Prescriber Benchmark Cards are still under review and Change Healthcare’s statistician is working on the data.

New Business

G. Master provided an overview of an educational outreach to prescribers to remind them of the importance of metabolic monitoring in children taking antipsychotic medications. The Board reviewed the letter.

She then presented a summary of topics for the quarterly DUR Digest. It was recommended to include a topic on emergency Telehealth rules.

Next, she presented a DUR Survey that included recommendations made by the DUR Committee. This survey accompanies the DUR interventions.

She also summarized various reports regarding prior authorization, claim count, and high cost medications.

Lastly, S. Baran presented emergency changes made to the pharmacy benefit in both Fee-for-Service and the Managed Care Plans in response to the COVID-19 pandemic. Following this presentation, a discussion ensued around how COVID-19 has affected the Board members’ practices.

Announcements

The dates for the next DUR Board meetings were set as follows:

- September 22, 2020
- November 10, 2020

Adjournment

The meeting was adjourned at 1:07 PM.